ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Indocyanine Green

Also written as “0.1 mg/kg ICG Dose”.

Its studies are mostly in Ischemia · Cholecystitis, Acute · Liver Failure, led by 3 companies.

Drug pageIndocyanine Green: every studyAll 105 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 15, 20153 company-led studies, 1 open or runningNext primary completion: Dec 1, 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cardiox10 open or runningphase 3since Sep 15, 2015Sep 15, 2015none ahead
Hamad Medicalits history only10 open or runningphase 4since Oct 30, 2020Oct 30, 2020none ahead
Researchits history only11 open or runningno phasesince Sep 1, 2026Sep 1, 2026Dec 1, 2026NCT07808957

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cardiox only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 15, 2015First study: phase 3 study in Liver FailureFirst studyNCT02552901 · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Cardiox leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02552901Liver Failure · United States3WithdrawnMay 20160

How it is read

Names in the registry

  • “Indocyanine Green”, 2 entries
  • “0.1 mg/kg ICG Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.